Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation

The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.

NCT Number	NCT07623473
Lead Sponsor	Herlev and Gentofte Hospital Collaborators: NEYE Foundation, Direktør Michael Hermann Nielsens mindelegat, afd B, Toyota Foundation Denmark, Grosserer L. F. Foghts Fond Denmark, Beckett Foundation, P. A. Messerschmidt & hustrus Fond
Conditions	Lung Cancer (Diagnosis), Nodule, Solitary Pulmonary
Enrollment	1,800 participants
Start Date	2024-05-22
Primary Completion	2028-02-01 (estimated)
Study Completion	2028-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-03